Top

Published in:

01-09-2006 | Topic Paper

Management of non-complicated BPH: proposition of a renewed decision tree

Authors: Francois Desgrandchamps, Alexandre de la Taille, Abdel-Rahmène Azzouzi, Marc Fourmarier, Olivier Haillot, Bertrand Lukacs, Christian Saussine, Comité des Troubles Mictionnels de l’Homme de l’Association Française d’Urologie (CTMH)

Published in: World Journal of Urology | Issue 4/2006

Abstract

Nowadays the management of benign prostatic hypertrophia (BPH) is undergoing striking changes. The standard medical treatments are represented by three families which are the phytotherapy, the alpha-blockers and the 5-alpha-reductase inhibitors. These treatments were deemed as symptomatic and used only as monotherapy. Recent numerous studies bring new assessments on BPH: the medical treatment is able to modify the natural history of BPH especially by reducing the risk of acute urinary retention. Furthermore the association of two different therapeutic classes seems to be more efficient than the use of a monotherapy in some cases. Similarly the place of two instrumental techniques, the thermotherapy by microwaves or by radiofrequencies, previously proposed as alternatives to the surgical treatment seems to find their way rather as alternatives to the medical treatment. These different elements allow building a renewed decision tree which decisions are shared with the patient at each stage. This decision tree of the management of patients having non-complicated BPH symptoms must include initial clinical characteristics of the patient and its disease and the evolution under treatment which has not been yet considered in the international recommendations. It also considers the possibilities of associations with other therapeutic classes.

Arrighi HM, Metter EJ, Guess HA, Fozzard JL (1991) Natural history of benign prostatic hyperplasia and risk of prostatectomy: the Baltimore longitudinal study of aging. Urology 38(1):4–8PubMedCrossRef

Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM (1993) The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 150(1):85–89PubMed

Guess HA, Chute CG, Garraway WM, Girman CJ, Panser LA, Lee RJ, Jacobsen SJ, McKelvie GB, Oesterling JE, Lieber MM (1993) Natural history of prostatism—urinary flow rates in a community-based study. J Urol 150(3):887–892PubMed

Piercy GB, Deber R, Trachtenberg J, Ramsey EW, Norman RW, Goldenberg SL, Nickel JC, Elhilali M, Perrault JP, Kraetschmer N, Sharpe N (1999) Impact of a shared decision-making program on patients with benign prostatic hyperplasia. Urology 53(5):913–920PubMedCrossRef

McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA (2003) Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. For the MTOPS research Group. The long term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2385–2396CrossRef

Lowe FC, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F, Dreikorn K, O’Leary M, Perez M, Speakman M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H (2005) Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion. Prostate Cancer Prostatic Dis 8(3):206–209PubMedCrossRef

Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarrete R, Nordling J, Roehrborn C, Schulman C, Teillac P, Tubaro A, Nickel JC (2003) Benign prostatic hyperplasia: a progressive disease of aging men. Urology 61(2):267–273PubMedCrossRef

Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, Melman A, Bracken RB, deVere White R, Taylor A, Wang D, Waldstreicher J (1999) Serum prostate specific antigen and prostate volume predict long term changes in symptoms and flow rate: results of a four year randomized trial comparing finasteride versus placebo. Urology 54(4):662–669PubMedCrossRef

Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001 ARIA3002, ARIA3003 Study Investigators (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434–441PubMedCrossRef

10.

Fitzpatrick JM, Desgrandchamps F (2005) The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. BJU Int 95(4):575–579PubMedCrossRef

11.

Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP (2002) Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 41(5):497–506PubMedCrossRef

12.

Kirby RS (2003) A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 91(1):41–44PubMedCrossRef

13.

Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC (2003) Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the triumph project. Eur Urol 44:539–545PubMedCrossRef

14.

Desgrandchamps F, Mongiat-Artus P (2006) Dosage and duration of medication for men with lower urinary tract symptoms: two questions without definitive answers. Curr Opin Urol 16(1):37–39PubMed

15.

Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44:461–466PubMedCrossRef

16.

Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94(6):817–820PubMedCrossRef

17.

Desgrandchamps F (2004) Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS. Curr Opin Urol 14(1):17–20PubMedCrossRef

18.

Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC (2003) Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 44:89–93PubMedCrossRef

19.

Tan AH, Nott L, Hardie WR, Chin JL, Denstedt JD, Razvi H (2005) Long-term results of microwave thermotherapy for symptomatic benign prostatic hyperplasia. J Endourol 19(10):1191–1195PubMedCrossRef

20.

Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46(5):547–554PubMedCrossRef

21.

AUA practice guidelines committee (2003) AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 170:530–547CrossRef

Title: Management of non-complicated BPH: proposition of a renewed decision tree
Authors: Francois Desgrandchamps
Alexandre de la Taille
Abdel-Rahmène Azzouzi
Marc Fourmarier
Olivier Haillot
Bertrand Lukacs
Christian Saussine
Comité des Troubles Mictionnels de l’Homme de l’Association Française d’Urologie (CTMH)
Publication date: 01-09-2006
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 4/2006
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-006-0096-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Management of non-complicated BPH: proposition of a renewed decision tree

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2006

The evolution of photoselective vaporization prostatectomy (PVP): advancing the surgical treatment of benign prostatic hyperplasia

First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?

Other therapies for BPH patients: desmopressin, anti-cholinergic, anti-inflammatory drugs, and botulinum toxin

How do I treat and follow my TUNA patients

Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays?

Transurethral microwave thermotherapy for the treatment of BPH: still a challenger?